Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...
Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...
Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Salesforce, Inc. (CRM), Shell plc ...
Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...
In multiple healthcare developments, Democratic states aim to safeguard Biden's rule for DACA immigrants, while ...
N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...
With incoming president Donald Trump threatening a trade war with China, experts told BioSpace that the new administration ...
Recent health news covers a proposed increase in Medicare Advantage rates, access challenges to precision cancer drugs for ...
The Macomb Daily on MSN4d
Macomb mom collaborates on children’s book for breast cancer familiesThe colorful picture book is helping parents of young children deal with the difficult journey that follows a breast cancer ...
Doxycycline postexposure prophylaxis has the potential to substantially reduce real-world population-level incidence of ...
the Royalty Agreement, under which Galapagos will gain full global development and commercialization rights to its pipeline, subject to payment of single digit royalties to Gilead on net sales of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback